Schley Katharina, Janßen Sabrina, Sullivan Shannon M, Tichy Eszter, Findlow Jamie
Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Evidera/PPD, 27-35, rue Victor Hugo, Ivry-sur-Seine CEDEX, 94853, France.
BMC Public Health. 2025 May 5;25(1):1653. doi: 10.1186/s12889-025-21491-3.
The invasive meningococcal disease (IMD) routine immunization recommendation in Germany is a meningococcal serogroup C (MenC) conjugate vaccine for toddlers aged 12 months with a catch-up for unimmunized up to 17 years. However, there are no recommendations for routine meningococcal serogroups A, C, W, Y (MenACWY) vaccination or for adolescent vaccinations; this differs from other European countries. This analysis aimed to understand the benefits of implementing adolescent MenACWY vaccination in Germany.
A static population-cohort model evaluating IMD burden and related health outcomes (e.g., cases, cases with long-term sequelae, deaths) was developed to compare any two meningococcal vaccination strategies. We compared hypothetical vaccination strategies that included different approaches to adolescent vaccination in Germany, such as vaccinating at 13-year olds versus 16-year olds and vaccinating with MenC versus MenACWY. Additional strategies considered the benefit that could be provided by switching the current MenC vaccine recommendation in toddlers to MenACWY.
All strategies that included MenACWY vaccine were effective in decreasing the number of cases, preventing mortality and offered good value for money. The greatest benefit was observed in individuals vaccinated with MenACWY at 12 months and 16 years of age (2,978 IMD cases averted; 563 IMD deaths prevented). Compared with the current strategy of MenC vaccination at 12 months of age, two-dose strategies that included MenACWY reported incremental cost-effectiveness ratios <€13,205 per quality-adjusted life year. Adolescent strategies of MenC or MenACWY vaccine at 16 years old (with no vaccination at 12 months) dominated current vaccination strategies. Adolescent vaccination at 16 years old versus 13 years old offered slightly better value for money.
With recent increases in IMD cases and outbreaks occurring globally following the COVID-19 pandemic, there is a greater urgency to proactively implement a MenACWY vaccine recommendation to protect adolescents in Germany. This recommendation would provide direct protection to a group at increased risk and offer indirect protection to other population groups. Implementation of a school-based immunization program could increase vaccine uptake and overcome hurdles in adolescent vaccination.
德国侵袭性脑膜炎球菌病(IMD)的常规免疫接种建议是为12个月大的幼儿接种C群脑膜炎球菌结合疫苗,并为17岁以下未接种疫苗的儿童进行补种。然而,对于A、C、W、Y群脑膜炎球菌(MenACWY)的常规疫苗接种或青少年疫苗接种尚无建议;这与其他欧洲国家不同。本分析旨在了解在德国实施青少年MenACWY疫苗接种的益处。
建立了一个静态人群队列模型,评估IMD负担及相关健康结局(如病例数、有长期后遗症的病例数、死亡数),以比较任意两种脑膜炎球菌疫苗接种策略。我们比较了假设的疫苗接种策略,这些策略包括德国青少年疫苗接种的不同方法,例如在13岁或16岁时接种,以及接种C群脑膜炎球菌疫苗(MenC)与MenACWY疫苗。其他策略考虑了将目前针对幼儿的MenC疫苗接种建议改为MenACWY疫苗接种可能带来的益处。
所有包含MenACWY疫苗的策略在减少病例数、预防死亡方面均有效,且性价比高。在12个月和16岁时接种MenACWY疫苗的个体获益最大(避免了2978例IMD病例;预防了563例IMD死亡)。与目前12个月龄接种MenC疫苗的策略相比,包含MenACWY疫苗的两剂次策略每质量调整生命年的增量成本效益比<13,205欧元。16岁时接种MenC或MenACWY疫苗的青少年策略(12个月时未接种)优于目前的疫苗接种策略。16岁接种疫苗相比13岁接种疫苗性价比略高。
随着COVID-19大流行后全球IMD病例数近期增加且出现疫情,德国迫切需要积极实施MenACWY疫苗接种建议以保护青少年。该建议将为风险增加的群体提供直接保护,并为其他人群提供间接保护。实施基于学校的免疫计划可提高疫苗接种率并克服青少年疫苗接种的障碍。